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Glioblastoma is the most common and malignant brain cancer in adults. Current therapy 
consisting of surgery followed by radiation and temozolomide has a moderate success 
rate and the tumor reappears. Among the features that a cancer cell must have to 
survive the therapeutic treatment and reconstitute the tumor is the ability of self-renewal. 
Therefore, it is vital to identify the molecular mechanisms that regulate this activity. Sex-
determining region Y (SRY)-box 2 (SOX2) is a transcription factor whose activity has 
been associated with the maintenance of the undifferentiated state of cancer stem cells 
in several tissues, including the brain. Several groups have detected increased SOX2 
levels in biopsies of glioblastoma patients, with the highest levels associated with poor 
outcome. Therefore, SOX2 silencing might be a novel therapeutic approach to combat 
cancer and particularly brain tumors. In this review, we will summarize the current knowl-
edge about SOX2 in glioblastoma and recapitulate several strategies that have recently 
been described targeting SOX2 in this malignancy.
Keywords: SOX2, glioblastoma, tumor-initiating cells, temozolomide resistance, glioma stem cells, self-renewal 
inhibition
SOX2
Sex-determining region Y (SRY)-box (SOX) factors are a family of transcriptional regulators that 
carry out important functions during embryonic development and which are key components for 
the maintenance of the stem cells in adult tissues. This family of transcription factors is characterized 
by a conserved high mobility group (HMG) DNA-binding domain and is composed of 20 members 
divided into 8 groups (from A to H), based on their HMG sequence identity (1). Members within a 
subfamily conserve at least 80% identity in their HMG-domain, in addition to sharing other well-
conserved regions. Moreover, members from the same group might have overlapping expression 
patterns, share biochemical properties, and perform synergistic or redundant functions. By contrast, 
members from different subgroups usually develop different functions (2).
SOX2 is a member of the SOXB1 group (together with SOX1 and SOX3), which is required for the 
maintenance of the embryo before implantation. SOX2 has a role in cell fate and maintenance of the 
progenitors’s identity during embryogenesis. It is also important for tissue homeostasis and regenera-
tion by maintaining stem cell activity in several compartments, particularly in the central nervous 
system (CNS), in adults (3). During recent years, several studies have demonstrated the impact 
of SOX2 deregulation in a wide variety of human diseases. A heterozygous inactivation of SOX2 
causes syndromic microphthalmia-3 (MCOPS3), a genetic disease characterized by anophthalmia, 
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microphthalmia mild hypopituitarism, and sometimes learning 
difficulties, convulsions, motor dysfunctions, and growth prob-
lems (4). On the contrary, SOX2 upregulation has been linked 
to the development and maintenance of several types of cancers 
(3, 5–7).
GLiOBLASTOMA
Tumors of the CNS form a heterogeneous group of diseases that 
comprise less than 2% of the total number of cancer cases. Every 
year in the world, ~350,000 people are diagnosed with gliomas, 
making it the most common primary brain tumor (8). According 
to clinical and histopathological characteristics, WHO classified 
them by four grades of malignancy: pylocitic astrocytoma (grade 
I); diffuse astrocytoma (grade II); anaplastic astrocytoma (grade 
III), and glioblastoma multiforme (GBM, grade IV). GBM is the 
most common, malignant, and lethal glioma subtype in adults 
accounting for 12–15% of all brain tumors and about 50% of glio-
mas. The incidence ranges from 1 to 5 cases per 100,000 people 
per year, with an average patient survival of around 15 months 
(8). This prognosis identifies this type of tumor as one of the 
most aggressive and fatal cancers overall. According to the clini-
cal presentation, there are two main GBM subtypes: primary or 
de novo GBM and secondary GBM. Primary tumors, the most 
common form, typically appear in older patients without any 
prior clinical or histological evidence of a lower grade precursor 
lesion and they have an aggressive clinical course. Secondary 
tumors are more frequent in younger people and they progress 
from a previous lower grade glioma with a less aggressive clinical 
course (9). Genetic and transcriptomic expression studies have 
allowed a more detailed molecular classification identifying four 
GBM subtypes: (i) classical, with EGFR amplification and overex-
pression, CDKN2A and PTEN deletion, NES overexpression and 
activation of NOTCH and SHH signaling pathways; (ii) mesen-
chymal, with  loss of NF1, TP53, and PTEN, overexpression of 
MET, CHI3L1, CD44, and MERTK, and activation of the TNF and 
NF-kB pathways; (iii) proneural, with PDGFR amplification, loss 
or mutation of IDH1, PIK3K, TP53, CDKN2A, and PTEN, and 
activation of HIF, PI3K, and PDGFR pathways; and (iv) neural, 
with EGFR amplification and overexpression, and expression of 
neuronal markers, such as NEFL, SYT1, and/or GABRA1 (10). 
Different subtypes are associated with variable prognosis and 
response to therapy, and this heterogeneity and this therapy 
resistance are likely the main characteristics responsible for the 
glioblastoma patients’ dismal outcome.
The cancer stem cell (CSC) theory postulates a hierarchically 
organized system in opposition to the stochastic model of tumor 
growth. The CSC model suggests that only a small group of cells 
have quiescence and self-renewal capacity within the tumor bulk, 
and that those are responsible for tumor maintenance and recur-
rence (11). Nowadays, there is a lot of evidence that supports the 
existence of CSCs in GBM, called glioma stem cells (GSC), and 
their relevance in the etiology of GBM. Several groups have been 
able to isolate GSCs from patient-derived tumors and multiple 
experimental data have shown that these cells are responsible for 
glioblastoma initiation and maintenance (12, 13), as well as for 
recurrence and chemoresistance (14–16). Moreover, there are 
different explanations for their origin. One of them proposes that 
neural stem cells (NSCs) undergo malignant transformation while 
retaining stem cell features. Indeed, inactivation of TP53, INK4a/
ARF locus, PTEN, and NF1 tumor suppressors or activation of 
EGFR/PDGFR/PI3K oncogenic pathways in NSCs induces high-
grade gliomas (17). Similarly, transient amplifying progenitors 
have been also shown as GSCs and the cell of origin of GBM (18). 
Another theory claims that more mature or differentiated cells are 
reprogrammed and form GSCs and high-grade gliomas. Indeed, 
several mutations in astrocytes, oligodendrocyte progenitors, or 
in neurons are sufficient to confer stem cell properties during 
neoplastic transformation (19, 20). Therefore, in order to establish 
efficient treatments that can induce a long-lasting clinical response 
in GBM, it is important to develop strategies that can specifically 
target GSCs (Figure  1A). CSCs, including GSCs, achieve self-
renewal through asymmetric division, in which one daughter 
cell retains the self-renewal ability, and the other is directed to 
differentiation. Moreover, heterogeneous tumor cell populations 
and their respective cell division mode have been shown to confer 
differential sensitivity to therapy in brain tumors (21). Therefore, 
modulation of asymmetric and symmetric division of GSCs may 
provide novel strategies for targeting differentially the GSC and 
the bulk tumor mass. Several drugs and approaches have been 
postulated (22) to directly target the GSCs population and/or 
the molecular mechanisms underlying their regulation. In this 
review, we focused our attention on targeting SOX2 gene.
SOX2 ACTiviTY AnD GBM
Several studies have identified an overexpression of SOX2 in 
GBM patient samples. It was first found elevated in 90% of human 
biopsies studied at the mRNA and protein level in 2007. This 
research also showed that SOX2 expression was restricted to the 
nucleus (23). Since then, overexpression of SOX2 (with varying 
percentages of positive cases) was observed in several different 
and independent cohorts (16, 24–27). Importantly, high levels 
of SOX2 have been associated with tumor aggressiveness and 
worse prognosis (28, 29). Moreover, several groups, including 
ours, identified SOX2 enrichment in the undifferentiated GSC 
populations and demonstrated that SOX2 possesses an impor-
tant role in the maintenance of GSCs. Indeed, downregulation 
of SOX2 through RNA interference strategies in GSCs impairs 
proliferation and their ability to form tumors in vivo (25, 30–32). 
Additionally, silencing of SOX2 leads to reduced migration and 
invasion capabilities (25, 33), while it increases senescence and 
produces an arrest of the cell cycle in G0/G1 (16, 34). The impact 
of SOX2 in glioblastoma cells has been further substantiated 
with overexpression studies. Indeed, ectopic elevation of 
SOX2 increases the capacity of invasion and migration (25), 
in addition to cell proliferation and self-renewal activity in 
conventional glioma cell lines (16). In agreement with this last 
function, SOX2 is one of the transcription factors, together with 
POU3F2, OLIG2, and SALL2, which is sufficient to reprogram 
differentiated glioma cells into induced GSCs, similar to GSCs 
obtained from human biopsies (35). Altogether these data show 
that glioma cells have a dependence on SOX2 to maintain their 
tumorigenic activity with GSCs displaying high levels of SOX2. 
TABLe 1 | Summary of relevant findings of SOX2 in glioblastoma.
Year Finding Reference
2007 SOX2 is overexpressed in human glioma 
samples
Schmitz et al. (23)
2009 Genetic SOX2 silencing impairs GSCs activity Gangemi et al. (30)
2011 Identification of SOX2 downstream targets in 
GBM with miRNA145–SOX2 feedback loop
Fang et al. (48)
2011 Genetic and epigenetic regulation of SOX2 in 
GBM samples
Alonso et al. (25)
2011 Identification of SOX2 as a target for 
combination treatments with tyrosine-kinase 
inhibitors
Hägerstrand et al. 
(32)
2011 Identification of SOX2 downstream of TGF-β 
signaling in GSCs
Ikushima et al. (31)
2014 Elevated SOX2 promotes dedifferentiation and 
acquisition of GSC characteristics in GBM cells
Suvà et al. (35)
2007 
and 
2014
First results supporting SOX2 mediated 
immunotherapy in mouse models and human 
samples
Schmitz et al. (23)
Favaro et al. (41)
2016 SOX2 induces chemoresistance, which is 
inhibited by rapamycin
Garros-Regulez 
et al. (16)
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FiGURe 1 | Significance of glioma stem cells (GSCs) and SOX2 targeting in the recurrence of glioblastoma. (A) Glioblastoma is a heterogeneous tumor 
composed of GSCs (in red, chemo-, and radiotherapy resistant) and of differentiated tumor cells (in blue, chemo-, and radiotherapy responsive). GSCs need to be 
targeted before current standard approaches to achieve tumor regression. TMZ, temozolomide; RT, radiotherapy. (B) In order to avoid tumor recurrence, genetic, 
epigenetic, and pharmacological approaches targeting GSCs expressing high levels of SOX2 have been postulated.
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They also demonstrate that SOX2 possesses an important role in 
the maintenance of GSCs.
In regard to a putative role of SOX2 controlling cell division 
modes, a recent work showed that the inhibition of the FACT 
chaperone complex in GSCs promotes their asymmetrical divi-
sion in a process that involves SOX2 downregulation (36). In line 
with these results, other authors found that the knockdown of 
HMGA1, a chromatin structure regulator, not only in GSCs but 
also in colon CSCs, induces an asymmetric division together with 
a decrease in SOX2 expression (37, 38). These works suggest that 
SOX2 action in the maintenance of undifferentiated GSCs could 
rely on effects promoting symmetrical in addition to the expected 
asymmetrical division. Importantly, these results support a hier-
archical model of glioma cells controlled by SOX2 expression, 
which brings up the idea to target SOX2 or to find downstream 
targetable genes as a strategy to eliminate GSCs and subsequently 
the tumor.
UPSTReAM ReGULATiOn OF SOX2
The regulation of SOX2 is a complex network of transcriptional, 
post-transcriptional, and post-translational regulators (Table 1). 
Some of these regulators are altered in GBM and lead to the over-
expression of SOX2. Four main signaling pathways are involved in 
SOX2 expression, including TGF-β, SHH, EGFR, and FGFR. All 
these signaling pathways are aberrantly activated in GBM, which 
leads to the maintenance of the tumor at least in part through 
SOX2 factor overexpression. The inhibition of TGF-β signaling 
decreases the tumorigenicity of GSCs by the suppression of SOX2 
activity (31). SOX2 function is also mediated by other members of 
the SOX family, such as SOX4, acting downstream of the TGF-β 
signaling pathway, and forming a complex with OCT4 at the SOX2 
promoter (31, 39). SHH pathway is initiated with the binding of 
SHH ligand to PTCH receptor, causing the activation of SMO. 
Active SMO will activate GLI1/2, which then translocates into 
the nucleus and activates SOX2. The regulation of SOX2 by SHH 
occurs in neural and brain stem cells (40, 41), and the pharma-
cological inhibition of these pathways silences SOX2 expression 
and impairs glioma cells’ tumorigenic activity (16). The FGFR 
pathway regulates SOX2 expression through two main signaling 
cascades: (i) MEK/ERK and (ii) PI3K/AKT/mTOR, two signaling 
pathways activated in GBM, and whose suppression leads to the 
inhibition of tumorigenesis and self-renewal of GSCs (42). The 
MEK/ERK pathway regulates the expression of SOX2 through the 
final phosphorylation of ERK, which translocates into the nucleus 
and activates the transcription of SOX2. The PI3K/AKT/mTOR 
pathway regulates positively the expression of SOX2 through 
the activation of the mammalian target of rapamycin complex 1 
(mTORC1). The inhibition of mTORC1 by rapamycin in GSCs 
leads to an inhibition of the SOX2 expression and a decrease in 
self-renewal activity (16). SOX2 is also regulated by EGFRvIII, 
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a frequent mutant in GBM that leads to the activation of pro-
oncogenic signaling in GBM. Indeed, the expression of EGFRvIII 
positively correlates with the expression of SOX2 and is associ-
ated with an enhanced self-renewal ability and tumor-initiating 
activity (43). This correlation has demonstrated that it is carried 
out by the axis EGFRvIII–STAT3–PEDF–Notch (44).
SOX2 can also be regulated via post-translational modifica-
tions, such as ubiquitination, phosphorylation, and acetylation. 
Acetylation and phosphorylation enhance the export of SOX2 to 
the cytoplasm and inhibit the ability to bind DNA in embryonic 
stem cells (45, 46). By contrast, the phosphorylation of SOX2 
by AKT stabilizes the protein and enhances the transcriptional 
activity of SOX2 (47). However, the function of these modifica-
tions in GSCs’ activity remains elusive.
Additionally, SOX2 genetic amplification and promoter DNA 
hypomethylation has been identified in a set of GBM patients, 
further expanding the mechanism responsible for SOX2 
upregulation in glioblastoma samples and GSCs (25). Moreover, 
the regulation of SOX2 through different miRNAs, including 
miRNA21 or miRNA145, has been described in glioma cells, with 
this axis having relevant functions in GSCs’ activity and in the 
clinic (29, 48).
DOwnSTReAM ReGULATiOn OF SOX2
Several studies have started to characterize downstream targets 
of SOX2 in glioblastoma. A study of Fang et al. identified SOX2 
downstream targets by ChIP-seq and microarray analyses in the 
LN229 glioma cell line. They found 4,883 SOX2 binding regions 
in the GBM cancer genome. Moreover, they detected 489 genes 
whose expression was altered with SOX2 inhibition, including 
additional SOX family members, cytokines, or BEX members 
with tumor suppressor activity in glioblastoma. They also identi-
fied 105 pre-miRNAs (corresponding to 95 mature miRNAs) that 
were differentially expressed in SOX2 knockdown glioblastoma 
cells. Among them, they observed that miRNA145 and SOX2 
form a double-negative feedback loop in GBM cells (48), dem-
onstrating that the relationship between SOX2 and miRNA is 
bidirectional. We have recently observed that several oncogenic 
SOX2 functions are mediated by SOX9, another member of the 
SOX family (16), which also carries out important functions in 
GSC regulation and glioblastoma (26). This regulation occurs at 
post-transcriptional level (16). Additionally, specific phenotypes 
associated with SOX2 have been linked to different genes and 
signaling pathways. Indeed, SOX2-regulated migratory and inva-
sive capacities are mediated by RhoA-dependent pathway and 
focal adhesion kinase (FAK) signaling, whereas proliferation is 
mediated by CYCLIN D1 expression (34). WNT signaling path-
way, self-renewal, and retinoic acid associated genes are within 
the genes involved in SOX2-mediated glioma cell plasticity and 
astrocytic differentiation (49).
THeRAPeUTiC APPROACHeS TOwARD 
SOX2 ReDUCTiOn in GBM
The current chemotherapeutic agent for newly diagnosed GBM 
is temozolomide (TMZ), which extends patient survival from 
12 to 15 months (50). A role for SOX2 in TMZ chemoresistance 
has been deciphered during recent years. Thus, cells with elevated 
SOX2 expression are more resilient to TMZ, whereas its inhibi-
tion sensitizes glioma cells to this agent (16). This cellular finding 
is correlated with clinical information. High levels of SOX2 have 
been included as a marker of the proneural subtype, which has 
been shown to be the most resistant subgroup to current therapeu-
tic radio- and chemotherapy treatment (10). The involvement of 
SOX2 in chemoresistance has been further substantiated through 
different mechanisms. The inhibition of SOX2 by miRNA145 
decreases the chemoresistance of GSCs and increases the sen-
sitivity to radiation and TMZ (51). The overexpression of ID-4 
suppresses the expression of miRNA9, that can repress SOX2, 
leading to an increase in the SOX2 expression. SOX2 induction 
enhances the ATP-binding cassette (ABC) transporters, ABCC3 
and ABCC6, through direct transcriptional regulation. The 
activation of ABC transporters confers chemoresistance to GSCs 
(52). These facts together with its prominent role in the regulation 
of GSCs suggest that SOX2 might be a key responsible factor for 
resistance to current chemotherapy and postulate that targeting 
its activity may offer a novel, attractive therapeutic approach to 
treat glioblastoma patients.
Several strategies are starting to use SOX2 directly or indirectly 
to target GSCs (Figure 1B). PDGFR signaling has been involved 
in glioblastoma biology through studies based on analyses of 
human tumor tissue, cultured glioblastoma cells, and mouse 
glioblastoma models (22). Similarly, IGF1-R signaling has been 
described in glioblastoma, and findings from preclinical studies 
suggest favorable combination effects when IGF1-R inhibitors 
have been combined with other receptor tyrosine-kinase (RTK)-
targeting agents. Interestingly, a combination therapy with PDGF 
and IGF1 receptor inhibitors (imatinib and NVP-AEW541) 
produces a significant tumor growth reduction through SOX2 
downregulation and GSC sensitization (32).
Rapamycin is an allosteric inhibitor of mTOR, which 
has been shown to dramatically reduce the self-renewal and 
tumorigenic activity of glioma cells and GSCs (53). In agree-
ment with these results, several phase I and II clinical trials, 
with some of its rapalogs, such as everolimus or temsirolimus, 
alone or in combination, showed radiographic and symptomatic 
evidence of improvement in delaying tumor progression without 
provoking high toxicity in patients with newly diagnosed or 
recurrent glioblastoma (54). It has recently been demonstrated 
that mTOR regulates the expression of SOX2. Genetic mTOR 
silencing or pharmacological treatment with rapamycin mark-
edly reduced SOX2 levels in glioma cells (16). Interestingly, 
the same work showed that the combination of rapamycin and 
TMZ was more efficient and displayed increased cytotoxicity 
in cells with high endogenous SOX2 levels (16). Cyclopamine, 
an inhibitor of the SHH pathway, was also proved effective in 
reducing SOX2 expression and inducing cytotoxicity in in vitro 
studies, but unlike rapamycin, its combination with TMZ did 
not increase the sensitivity of glioma cells to chemotherapy (16). 
Furthermore, several studies have demonstrated the capability 
of the GSCs to transdifferentiate into tumor-derived vascular 
endothelial and mural-like cells in a VEGF-independent manner, 
making the tumor resistant to anti-vascular therapy (55, 56). This 
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transdifferentiation relies on high levels of NESTIN and CD133 
stem markers; however, SOX2 has not been evaluated. It would 
be of interest to determine the role of SOX2 in transdifferentia-
tion and if knocking down its expression levels is sufficient to 
prevent the process.
Alternative treatments are arising using SOX2 protein as the 
principal target of new therapies. Immunotherapy represents 
a promising treatment option to improve the clinical outcome 
of patients suffering from GBM. In 2014, Dr Nicolis’ group did 
transplants of GSCs in mice brains using peptide vaccination 
against SOX2. Peptide vaccination alone increased the mice’ 
survival and the vaccination in combination with the current 
treatment with TMZ doubled the mice’ survival time (41). Before, 
Schmitz and coworkers identified SOX2 as a glioma-associated 
antigen abundantly and specifically overexpressed in glioma 
cells. In addition, they identified an immunogenic HLA-A*0201-
restricted T-cell epitope derived from SOX2 that effectively acti-
vated tumor-directed cytotoxic T lymphocytes (23). These results 
highlight the suitability of SOX2 for a novel strategy based in 
immunotherapy in monotherapy or in combination with current 
therapies for the treatment of glioblastoma patients.
The use of miRNA delivery could be another therapy linked to 
SOX2 for cancer cells in the brain. As described above, miRNA145 
is associated with SOX2. Interestingly, miRNA145 delivery in 
GSCs and in xenograft studies in vivo demonstrated the ability to 
suppress the tumorigenicity by direct downregulation of SOX2 
protein with cells becoming more sensitive to chemotherapeutic 
agents, such as TMZ or cisplatin (51). The promising therapeutic 
prospect of miR-145 might improve current cancer treatments, 
especially for those tumors that have developed a resistance to 
conventional therapeutic methods. However, a note of caution 
needs to be included since the use of viral vectors for gene 
delivery may be accompanied by several problems, including an 
immune response.
COnCLUDinG ReMARKS
Glioblastoma is the most common and malignant adult primary 
brain tumor with a dismal patient prognosis. It is characterized 
by presenting significant heterogeneity at the genetic, molecular, 
cellular, and morphological level, which severely affects clinical 
practice. Tumor bulk is formed by differentiated cells targetable 
with chemo- and radiotherapy and GSCs, which need to be 
eradicated in order to achieve effective therapeutic response.
Sex-determining region Y (SRY)-box 2 transcription factor is 
important during embryonic development and for the mainte-
nance of stem cell properties of the CNS in adult and aged stages 
(3, 57, 58). It is also a key regulator of stemness in CSCs and its 
biological function has been widely described in GBM, associ-
ated with stemness activity and a poor clinical outcome (Table 1). 
Therefore, SOX2 is a strong molecular candidate to be targeted in 
glioblastoma samples and the potential benefit of SOX2 targeting 
in the scenario of such a lethal tumor is not negligible. However, 
a point to take into account with regard to SOX2 targeting for 
GBM treatment is that other SOX2 expressing cell populations as 
astrocytes, which develop relevant roles in neurogenesis, could 
be susceptible to the treatments. The consequences of this must 
be evaluated and other molecules acting downstream of SOX2, 
and more specific of GSCs, should be identified and considered 
as targets.
Transcriptional regulation and/or post-transcriptional sup-
pression of SOX2 through miRNA regulation are promising 
approaches. There are also encouraging results with SOX2 immu-
notherapy or combining tyrosine-kinase and IGF1 inhibitors. 
These results show the preclinical proof of concept that silencing 
SOX2 activity is an effective strategy in glioblastoma. More solid 
and extensive preclinical results and clinical trials with the pos-
tulated combination of therapies in glioblastoma patients whose 
biopsies express elevated SOX2 are needed to establish their 
clinical impact.
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